Diabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes

Boris P Kovatchev, Boris P Kovatchev

Abstract

People with diabetes face a life-long optimization problem: to maintain strict glycemic control without increasing their risk for hypoglycemia. Since the discovery of insulin in 1921, the external regulation of diabetes by engineering means has became a hallmark of this optimization. Diabetes technology has progressed remarkably over the past 50 years-a progress that includes the development of markers for diabetes control, sophisticated monitoring techniques, mathematical models, assessment procedures, and control algorithms. Continuous glucose monitoring (CGM) was introduced in 1999 and has evolved from means for retroactive review of blood glucose profiles to versatile reliable devices, which monitor the course of glucose fluctuations in real time and provide interactive feedback to the patient. Technology integrating CGM with insulin pumps is now available, opening the field for automated closed-loop control, known as the artificial pancreas. Following a number of in-clinic trials, the quest for a wearable ambulatory artificial pancreas is under way, with a first prototype tested in outpatient setting during the past year. This paper discusses key milestones of diabetes technology development, focusing on the progress in the past 10 years and on the artificial pancreas-still not a cure, but arguably the most promising treatment of diabetes to date.

Figures

Figure 1
Figure 1
The Diabetes technology timeline from the discovery of insulin to the introduction of continuous glucose monitoring.
Figure 2
Figure 2
Timeline of the artificial pancreas developments in the last decade—theoretical work and a number of in-clinic studies leading to the first trials of wearable artificial pancreas device.

References

    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:s5–s10.
    1. Kadish AH. Automation control of blood sugar—I. A servomechanism for glucose monitoring and control. American Journal of Medical Electronics. 1964;39:82–86.
    1. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. British Medical Journal. 1978;1(6107):204–207.
    1. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. New England Journal of Medicine. 1979;300(11):573–578.
    1. Albisser AM, Leibel BS, Ewart TG. An artificial endocrine pancreas. Diabetes. 1974;23(5):389–396.
    1. Pfeiffer EF, Thum Ch., Clemens AH. The artificial beta cell: a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system) Hormone and Metabolic Research. 1974;6(5):339–342.
    1. Mirouze J, Selam JL, Pham TC, Cavadore D. Evaluation of exogenous insulin homoeostasis by the artifical pancreas in insulin dependent diabetes. Diabetologia. 1977;13(3):273–278.
    1. Kraegen EW, Campbell LV, Chia YO. Control of blood glucose in diabetics using an artificial pancreas. Australian and New Zealand Journal of Medicine. 1977;7(3):280–286.
    1. Shichiri M, Kawamori R, Yamasaki Y, Inoue M, Shigeta Y, Abe H. Computer algorithm for the artificial pancreatic beta cell. Artificial Organs. 1978;2, supplement:247–250.
    1. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS) Hormone and Metabolic Research. 1977;7:23–33.
    1. Marliss EB, Murray FT, Stokes EF. Normalization of glycemia in diabetics during meals with insulin and glucagon delivery by the artificial pancreas. Diabetes. 1977;26(7):663–672.
    1. Santiago JV, Clemens AH, Clarke WL, Kipnis DM. Closed-loop and open-loop devices for blood glucose control in normal and diabetic subjects. Diabetes. 1979;28(1):71–84.
    1. Fischer U, Jutzi E, Freyse EJ, Salzsieder E. Derivation and experimental proof of a new algorithm for the artificial B-cell based on the individual analysis of the physiological insulin-glucose relationship. Endokrinologie. 1978;71(1):65–75.
    1. Parker RS, Doyle FJ, Peppas NA. The intravenous route to blood glucose control: a review of control algorithms for noninvasive monitoring and regulation in type I diabetic patients. IEEE Engineering in Medicine and Biology Magazine. 2001;20(1):65–73.
    1. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. The American Journal of Physiology. 1979;236(6):E667–E677.
    1. Broekhuyse HM, Nelson JD, Zinman B, Albisser AM. Comparison of algorithms for the closed-loop control of blood glucose using the artificial beta cell. IEEE Transactions on Biomedical Engineering. 1981;28(10):678–687.
    1. Clemens AH. Feedback control dynamics for glucose controlled insulin infusion system. Medical Progress through Technology. 1979;6(3):91–98.
    1. Cobelli C, Ruggeri A. Evaluation of portal/peripheral route and of algorithms for insulin delivery in the closed-loop control of glucose in diabetes: a modeling study. IEEE Transactions on Biomedical Engineering. 1983;30(2):93–103.
    1. Salzsieder E, Albrecht G, Fischer U, Freyse EJ. Kinetic modeling of the glucoregulatory system to improve insulin therapy. IEEE Transactions on Biomedical Engineering. 1985;32(10):846–855.
    1. Brunetti P, Cobelli C, Cruciani P, et al. A simulation study on a self-tuning portable controller of blood glucose. International Journal of Artificial Organs. 1993;16(1):51–57.
    1. Fischer U, Schenk W, Salzsieder E, Albrecht G, Abel P, Freyse EJ. Does physiological blood glucose control require an adaptive control strategy? IEEE Transactions on Biomedical Engineering. 1987;34(8):575–582.
    1. Sorensen JT. A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes [Ph.D. dissertation] Department of Chemical Engineering, MIT; 1985.
    1. Parker RS, Doyle FJ, Peppas NA. A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Transactions on Biomedical Engineering. 1999;46(2):148–157.
    1. Mastrototaro JJ. The MiniMed continuous glucose monitoring System. Diabetes Technology and Therapeutics. 2000;2(1):S13–S18.
    1. Bode BW. Clinical utility of the continuous glucose monitoring system. Diabetes Technology and Therapeutics. 2000;2(1, supplement):S35–S41.
    1. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology—results from a 3-day trial in patients with type 1 diabetes. Diabetes Technology and Therapeutics. 2003;5(5):769–779.
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:978–986.
    1. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968–983.
    1. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes. 2008;57(4):995–1001.
    1. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes. 1994;43(2):313–317.
    1. UK Prospective Diabetes Study Group (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352(9131):837–853.
    1. Svendsen PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia. 1982;23(5):403–405.
    1. Santiago JV. Lessons from the diabetes control and complications trial. Diabetes. 1993;42(11):1549–1554.
    1. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46:271–286.
    1. Gold AE, Frier BM, MacLeod KM, Deary IJ. A structural equation model for predictors of severe hypoglycaemia in patients with insulin-dependent diabetes mellitus. Diabetic Medicine. 1997;14:309–315.
    1. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. Journal of Clinical Endocrinology and Metabolism. 1994;79(6):1659–1662.
    1. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care. 1998;21(11):1870–1875.
    1. Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technology and Therapeutics. 2003;5(5):817–828.
    1. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care. 2007;30(6):1370–1373.
    1. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes. 1988;37(7):901–907.
    1. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. New England Journal of Medicine. 1987;316(22):1376–1383.
    1. Cryer PE, Gerich JE. Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. New England Journal of Medicine. 1985;313(4):232–241.
    1. White NH, Skor DA, Cryer PE. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. New England Journal of Medicine. 1983;308(9):485–491.
    1. Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious cycle. Diabetes. 1992;41(3):255–260.
    1. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabetic Medicine. 2003;20(12):1016–1021.
    1. Cryer PE. Hypoglycemia. Pathophysiology, Diagnosis and Treatment. New York, NY, USA: Oxford University Press; 1997.
    1. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–1912.
    1. Childs BP, Clark NG, Cox DJ. Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia. Diabetes Care. 2005;28(5):1245–1249.
    1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45(7):937–948.
    1. Cryer PE. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 1994;43(11):1378–1389.
    1. McCall AL, Kovatchev BP. The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. Journal of Diabetes Science and Technology. 2009;3:3–11.
    1. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. Journal of the American Medical Association. 2006;295(14):1707–1708.
    1. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? Journal of Diabetes and Its Complications. 2005;19(3):178–181.
    1. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214–219.
    1. Haffner S. The importance of postprandial hyperglycaemia in development of cardiovascular disease in people with diabetes: point. International Journal of Clinical Practice. 2001;(123):24–26.
    1. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Journal of the American Medical Association. 2006;295(14):1681–1687.
    1. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA(1c) level. Diabetes Care. 2000;23(12):1830–1834.
    1. Clarke WL, Cox DJ, Gonder-Frederick L, Julian D, Kovatchev B, Young-Hyman D. Biopsychobehavioral model of risk of severe hypoglycemia: self-management behaviors. Diabetes Care. 1999;22(4):580–584.
    1. Cox DJ, Gonder-Frederick LA, Kovatchev BP, et al. Biopsychobehavioral model of severe hypoglycemia II: understanding the risk of severe hypoglycemia. Diabetes Care. 1999;22(12):2018–2025.
    1. Gonder-Frederick L, Cox D, Kovatchev B, Schlundt D, Clarke W. A biopsychobehavioral model of risk of severe hypoglycemia. Diabetes Care. 1997;20(4):661–669.
    1. Kovatchev B, Cox D, Gonder-Frederick L, Schlundt D, Clarke W. Stochastic model of self-regulation decision making exemplified by decisions concerning hypoglycemia. Health Psychology. 1998;17(3):277–284.
    1. Nucci G, Cobelli C. Models of subcutaneous insulin kinetics. A critical review. Computer Methods and Programs in Biomedicine. 2000;62(3):249–257.
    1. Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R. Insulin kinetics in type-1 diabetes: continuous and bolus delivery of rapid acting insulin. IEEE Transactions on Biomedical Engineering. 2005;52(1):3–12.
    1. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrine Reviews. 1985;236:E667–E677.
    1. Bergman RN. The minimal model of glucose regulation: a biography. Advances in Experimental Medicine and Biology. 2003;537:1–19.
    1. Bergman RN, Zaccaro DJ, Watanabe RM, et al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes. 2003;52(8):2168–2174.
    1. Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. Journal of Clinical Endocrinology and Metabolism. 2000;85(11):4396–4402.
    1. Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians: analysis of the impact of gender, body fat, physical fitness, and life-style factors. Journal of Clinical Investigation. 1996;98(5):1195–1209.
    1. Ni TC, Ader M, Bergman RN. Reassessment of glucose effectiveness and insulin sensitivity from minimal model analysis: a theoretical evaluation of the single-compartment glucose distribution assumption. Diabetes. 1997;46(11):1813–1821.
    1. Welch S, Gebhart SSP, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. Journal of Clinical Endocrinology and Metabolism. 1990;71(6):1508–1518.
    1. Dawson D, Vincent MA, Barrett EJ, et al. Capillary recruitment in skeletal muscle in response to exercise and hyperinsulinemia assessed with contrast-enhanced ultrasound. American Journal of Physiology. 2002;282(3):E714–E720.
    1. Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of physical exercise on sensitivity and responsiveness to insulin in humans. American Journal of Physiology. 1988;254(3):E248–E259.
    1. Richter EA. Glucose utilization. In: Rowell LB, Shepherd JT, editors. Handbook of Physiology. New York, NY, USA: Oxford University Press; 1996. pp. 912–951.
    1. Wasserman DH, Geer RJ, Rice DE, et al. Interaction of exercise and insulin action in humans. American Journal of Physiology. 1991;260(1):E37–E45.
    1. Pillonetto G, Caumo A, Sparacino G, Cobelli C. A new dynamic index of insulin sensitivity. IEEE Transactions on Biomedical Engineering. 2006;53(3):369–379.
    1. Dalla Man C, Raimondo DM, Rizza RA, Cobelli C. GIM, Simulation software of meal glucose-insulin model. Journal of Diabetes Science and Technology. 2007;1:323–330.
    1. Dalla Man C, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Transactions on Biomedical Engineering. 2007;54(10):1740–1749.
    1. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care. 1987;10(5):622–628.
    1. The Diabetes Research In Children Network (Direcnet) Study Group. A multicenter study of the accuracy of the one touch ultra home glucose meter in children with type 1 diabetes. Diabetes Technology and Therapeutics. 2003;5(6):933–941.
    1. Hirsch IB, Bode BW, Childs BP, et al. Self-monitoring of blood glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. Diabetes Technology and Therapeutics. 2008;10(6):419–439.
    1. Freckmann G, Baumstark A, Jendrike N, et al. System accuracy evaluation of 27 blood glucose monitoring systems according to DIN en ISO 15197. Diabetes Technology and Therapeutics. 2010;12(3):221–231.
    1. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730–2732.
    1. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44–50.
    1. Kovatchev BP, Clarke WL. Continuous glucose monitoring reduces risks for hypo- and hyperglycemia and glucose variability in diabetes. Diabetes. 2007;56(1)0086OR
    1. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine. 2008;359:1464–1476.
    1. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005;28(5):1231–1239.
    1. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetic Medicine. 2006;23(1):1–12.
    1. Klonoff DC. The artificial pancreas: how sweet engineering will solve bitter problems. Journal of Diabetes Science and Technology. 2007;1:72–81.
    1. Hirsch IB, Armstrong D, Bergenstal RM, et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM) Diabetes Technology and Therapeutics. 2008;10(4):232–246.
    1. Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. American Journal of Physiology. 1999;277(3):E561–E571.
    1. Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technology and Therapeutics. 2000;2(3):461–472.
    1. Steil GM, Rebrin K, Hariri F, et al. Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia. Diabetologia. 2005;48(9):1833–1840.
    1. Boyne MS, Silver DM, Kaplan J, Saudek CD. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes. 2003;52(11):2790–2794.
    1. Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ. Physiological differences between interstitial glucose and blood glucose measured in human subjects. Diabetes Care. 2003;26(8):2405–2409.
    1. Stout PJ, Racchini JR, Hilgers ME. A novel approach to mitigating the physiological lag between blood and interstitial fluid glucose measurements. Diabetes Technology and Therapeutics. 2004;6(5):635–644.
    1. Wentholt IME, Hart AAM, Hoekstra JBL, Devries JH. Relationship between interstitial and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon revisited. Diabetes Technology and Therapeutics. 2007;9(2):169–175.
    1. Wientjes KJC, Schoonen AJM. Determination of time delay between blood and interstitial adipose tissue glucose concentration change by microdialysis in healthy volunteers. International Journal of Artificial Organs. 2001;24(12):884–889.
    1. Aussedat B, Dupire-Angel M, Gifford R, Klein JC, Wilson GS, Reach G. Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. American Journal of Physiology. 2000;278(4):E716–E728.
    1. Kovatchev BP, Clarke WL. Peculiarities of the continuous glucose monitoring data stream and their impact on developing closed-loop control technology. Journal of Diabetes Science and Technology. 2008;2:158–163.
    1. Clarke WL, Kovatchev BP. Continuous glucose sensors—continuing questions about clinical accuracy. Journal of Diabetes Science and Technology. 2007;1:164–170.
    1. The Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the guardian RT continuous glucose monitor in children with type 1 diabetes. Diabetes Technology and Therapeutics. 2008;10:266–272.
    1. Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31(6):1160–1164.
    1. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the navigator continuous glucose monitoring systems. Diabetes Technology and Therapeutics. 2009;11(2):65–72.
    1. Heise T, Koschinsky T, Heinemann L, Lodwig V. Hypoglycemia warning signal and glucose sensors: requirements and concepts. Diabetes Technology and Therapeutics. 2003;5(4):563–571.
    1. Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the Guardian continuous monitoring system. Diabetes Technology and Therapeutics. 2004;6(2):105–113.
    1. McGarraugh G, Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle navigator continuous glucose monitoring system. Diabetes Technology and Therapeutics. 2009;11(3):145–150.
    1. Noujaim SE, Horwitz D, Sharma M, Marhoul J. Accuracy requirements for a hypoglycemia detector: an analytical model to evaluate the effects of bias, precision, and rate of glucose change. Journal of Diabetes Science and Technology. 2007;1:653–668.
    1. Ward WK. The role of new technology in the early detection of hypoglycemia. Diabetes Technology and Therapeutics. 2004;6(2):115–117.
    1. Buckingham B, Cobry E, Clinton P, et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technology and Therapeutics. 2009;11(2):93–97.
    1. Hughes CS, Patek SD, Breton MD, Kovatchev BP. Hypoglycemia prevention via pump attenuation and red-yellow-green “traffic” lights using continuous glucose monitoring and insulin pump data. Journal of Diabetes Science and Technology. 2010;4(5):1146–1155.
    1. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care. 1997;20(11):1655–1658.
    1. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644–655.
    1. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood glucose control in diabetics. Acta Medica Scandinavica. 1965;177:95–102.
    1. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lambility in type 1 diabetic subjects undergoing islet in transplantation. Diabetes. 2004;53(4):955–962.
    1. Kovatchev BP, Cox DJ, Gonder-Frederick L, Clarke WL. Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technology and Therapeutics. 2002;4(3):295–303.
    1. Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. Journal of Clinical Endocrinology and Metabolism. 2000;85(11):4287–4292.
    1. Kovatchev BP, Straume M, Cox DJ, Farhy LS. Risk analysis of blood glucose data: a quantitative approach to optimizing the control of Insulin Dependent Diabetes. Journal of Theoretical Medicine. 2000;3(1):1–10.
    1. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433–2438.
    1. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technology and Therapeutics. 2005;7(6):849–862.
    1. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technology and Therapeutics. 2009;11(9):551–565.
    1. Miller M, Strange P. Use of Fourier models for analysis and interpretation of continuous glucose monitoring glucose profiles. Journal of Diabetes Science and Technology. 2007;1:630–638.
    1. Clarke W, Kovatchev B. Statistical tools to analyze continuous glucose monitor data. Diabetes Technology and Therapeutics. 2009;11:S45–S54.
    1. Mcdonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technology and Therapeutics. 2005;7(2):253–263.
    1. Sparacino G, Zanderigo F, Maran A, Cobelli C. Continuous glucose monitoring and hypo/hyperglycaemia prediction. Diabetes Research and Clinical Practice. 2006;74(2, supplement):S160–S163.
    1. Sparacino G, Zanderigo F, Corazza G, Maran A, Facchinetti A, Cobelli C. Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series. IEEE Transactions on Biomedical Engineering. 2007;54:931–937.
    1. Reifman J, Rajaraman S, Gribok A, Ward WK. Predictive monitoring for improved management of glucose levels. Journal of Diabetes Science and Technology. 2007;1:478–486.
    1. Zanderigo F, Sparacino G, Kovatchev B, Cobelli C. Glucose prediction algorithms from continuous monitoring: assessment of accuracy via continuous glucose-error grid analysis. Journal of Diabetes Science and Technology. 2007;1:645–651.
    1. Cameron F, Niemayer G, Gundy-Burlet K, Buckingham B. Statistical hypoglycemia prediction. Journal of Diabetes Science and Technology. 2008;2:612–621.
    1. Gani A, Gribok AV, Rajaraman S, Ward WK, Reifman J. Predicting subcutaneous glucose concentration in humans: data-driven glucose modeling. IEEE Transactions on Biomedical Engineering. 2009;56(2):246–254.
    1. Eren-Oruklu M, Cinar A, Quinn L, Smith D. Estimation of future glucose concentrations with subject-specific recursive linear models. Diabetes Technology and Therapeutics. 2009;11(4):243–253.
    1. Pappada SM, Cameron BD, Rosman PM. Development of a neural network for prediction of glucose concentration in type 1 diabetes patients. Journal of Diabetes Science and Technology. 2008;2:792–801.
    1. Cobelli C, Dalla Man C, Sparacino G, Magni L, Nicolao G, Kovatchev BP. Diabetes: models, signals, and control. IEEE Reviews in Biomedical Engineering. 2009;2:54–96.
    1. LeBlanc H, Chauvet D, Lombrail P, Robert JJ. Glycemic control with closed-loop intraperitoneal insulin in type I diabetes. Diabetes Care. 1986;9(2):124–128.
    1. Saudek CD, Selman JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. New England Journal of Medicine. 1989;321(9):574–579.
    1. Broussolle C, Jeandidier N, Hanaire-Broutin H. French multicentre experience of implantable insulin pumps. Lancet. 1994;343(8896):514–515.
    1. Hanaire-Broutin H, Broussolle C, Jeandidier N, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: a multicenter study. Diabetes Care. 1995;18(3):388–392.
    1. Oskarsson PR, Lins PE, Henriksson HW, Adamson UC. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. Diabetes and Metabolism. 1999;25(6):491–497.
    1. Oskarsson PR, Lins PE, Backman L, Adamson UC. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. Diabetes and Metabolism. 2000;26(2):118–124.
    1. Catargi B, Meyer L, Melki V, Renard E, Jeandidier N. Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 hoe 21pH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes and Metabolism. 2002;28(2):133–137.
    1. Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Current Opinion in Pharmacology. 2002;2(6):708–716.
    1. Renard E, Costalat G, Chevassus H, Bringer J. Artificial β-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes and Metabolism. 2006;32(5):497–502.
    1. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care. 2010;33(1):121–127.
    1. Bellazzi R, Nucci G, Cobelli C. The subcutaneous route to insulin-dependent diabetes therapy: closed-loop and partially closed-loop control strategies for insulin delivery and measuring glucose concentration. IEEE Engineering in Medicine and Biology Magazine. 2001;20(1):54–64.
    1. Hovorka R, Chassin LJ, Wilinska ME, et al. Closing the loop: the adicol experience. Diabetes Technology and Therapeutics. 2004;6(3):307–318.
    1. Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiological Measurement. 2004;25(4):905–920.
    1. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344–3350.
    1. The JDRF e-Newsletter: Emerging Technologies in Diabetes Research, 2006.
    1. Clarke WL, Kovatchev B. The artificial pancreas: how close are we to closing the loop? Pediatric Endocrinology Reviews. 2007;4(4):314–316.
    1. Cobelli C, Renard E, Kovatchev BP. Perspectives in diabetes: artificial pancreas: past, present, future. Diabetes. 2011;60:2672–2682.
    1. Kovatchev BP, Breton MD, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. Journal of Diabetes Science and Technology. 2009;3:44–55.
    1. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. Journal of Diabetes Science and Technology. 2010;4(6):1374–1381.
    1. Zisser H, Jovanovic L, Doyle F, Ospina P, Owens C. Run-to-run control of meal-related insulin dosing. Diabetes Technology and Therapeutics. 2005;7(1):48–57.
    1. Owens C, Zisser H, Jovanovic L, Srinivasan B, Bonvin D, Doyle FJ., III Run-to-run control of blood glucose concentrations for people with type 1 diabetes mellitus. IEEE Transactions on Biomedical Engineering. 2006;53(6):996–1005.
    1. Palerm CC, Zisser H, Bevier WC, Jovanovič L, Doyle FJ., III Prandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric. Diabetes Care. 2007;30(5):1131–1136.
    1. Magni L, Raimondo F, Bossi L, et al. Model predictive control of type 1 diabetes: an in silico trial. Journal of Diabetes Science and Technology. 2007;1:804–812.
    1. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934–939.
    1. Clarke WL, Anderson S, Breton M, Patek S, Kashmer L, Kovatchev B. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. Journal of Diabetes Science and Technology. 2009;3(5):1031–1038.
    1. Bruttomesso D, Farret A, Costa S, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. Journal of Diabetes Science and Technology. 2009;3(5):1014–1021.
    1. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. The Lancet. 2010;375(9716):743–751.
    1. El-khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Science Translational Medicine. 2010;2(27)27ra27
    1. Dassau E, Zisser H, Palerm CC, Buckingham BA, Jovanovič L, Doye FJ., III Modular artificial β-cell system: a prototype for clinical research. Journal of Diabetes Science and Technology. 2008;2:863–872.
    1. Kovatchev B, Patek S, Dassau E, et al. Control to range for diabetes: functionality and modular architecture. Journal of Diabetes Science and Rechnology. 2009;3(5):1058–1065.
    1. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care. 2010;33(5):1072–1076.
    1. Dassau E, Zisser H, Percival MW, Grosman B, Jovanovič L, Doyle FJ., III Clinical results of automated artificial pancreatic β-cell system with unannounced meal using multi-parametric MPC and insulin-on-board. Proceedings of the 70th American Diabetes Association Meeting; 2010; Orlando, Fla, USA.
    1. Renard EM, Farret A, Place J, Cobelli C, Kovatchev BP, Breton MD. Closed-loop insulin delivery using subcutaneous infusion and glucose sensing, and equipped with a dedicated safety supervision algorithm, improves safety of glucose control in type 1 diabetes. Diabetologia. 2010;53, supplement 1:p. S25.
    1. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomized controlled studies. British Medical Journal. 2011;342(7803)d1855
    1. Zisser H, Dassau E, Bevier W, et al. Initial evaluation of a fully automated artificial pancreas. Proceedings of the 71st American Diabetes Association Meeting; 2011; San Diego, Calif, USA.
    1. Breton MD, Farret A, Bruttomesso D. Fully-integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near-normoglycemia. Diabetes. 2012;61:2230–2237.
    1. Cobelli C, Renard E, Kovatchev BP. Pilot studies of wearable artificial pancreas in type 1 diabetes. Diabetes Care. 2012;35(9):e65–e67.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe